Similar articles

• Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.

  Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H. Ikeda M, et al. J Gastroenterol. 2005 Feb;40(2):148-56. doi: 10.1007/s00535-004-1519-2. J Gastroenterol. 2005. PMID: 15770398
• Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.

  Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N. Imai Y, et al. J Viral Hepat. 2010 Mar;17(3):185-91. doi: 10.1111/j.1365-2893.2009.01163.x. Epub 2009 Aug 26. J Viral Hepat. 2010. PMID: 19709362
• Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.

  Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, Kaneko M, Goto I, Tanaka N, Arakawa Y. Moriyama M, et al. Liver Int. 2005 Feb;25(1):85-90. doi: 10.1111/j.1478-3231.2005.01028.x. Liver Int. 2005. PMID: 15698403
• [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].

  Nishiguchi S, Kubo S, Shiomi S. Nishiguchi S, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):600-4. Nihon Rinsho. 2004. PMID: 15359868 Review. Japanese. No abstract available.
• Hepatitis C and interferon: fewer cases of liver cancer.

  [No authors listed] [No authors listed] Prescrire Int. 2013 Jul;22(140):191. Prescrire Int. 2013. PMID: 23951600 Review.